Isomorphic Labs secures $2.1B funding to scale AI drug design engine

Isomorphic Labs, an AI-first drug design and development company, announced it has raised $2.1B in Series B funding. This latest round of investment will accelerate the company’s evolution from pioneering novel AI models to applying them at scale, the company said. The financing round is led by Thrive Capital, and includes participation from existing backers Alphabet (GOOG) (GOOGL) and GV alongside new investors MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, significantly expanding Isomorphic Labs’ global capital base. The new capital will be used for the continued development and deployment of Isomorphic Labs’ AI drug design engine, accelerating and expanding its pipeline of therapeutic programs towards the clinic. Additionally, the funding will support existing hiring targets by integrating world-class AI, engineering, drug design, and clinical talent across sites.